The clinical spectrum of Fontan-associated liver disease: results from a prospective multimodality screening cohort.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
01 04 2019
Historique:
received: 16 04 2018
revised: 04 07 2018
accepted: 14 09 2018
pubmed: 23 10 2018
medline: 6 6 2020
entrez: 23 10 2018
Statut: ppublish

Résumé

Liver fibrosis and cirrhosis are a consequence of a Fontan physiology, and determine prognosis. It is unclear whether non-invasive assessment of liver pathology is helpful to provide clinically relevant information. The aims of this study were to assess the spectrum of Fontan-associated liver disease (FALD) and usefulness of non-invasive methods to assess biopsy confirmed liver fibrosis. Hepatic screening of consecutive patients consisted of a blood panel, ultrasonography, elastography, contrast-enhanced magnetic resonance imaging (MRI)/computed tomography (CT) scan, and liver biopsy (scored with Fontan specific fibrosis scores and collagen proportionate area; CPA). Fibrosis parameters, varices, ascites, and splenomegaly were measured on imaging. Thirty-eight of 49 referred patients (27 ± 6.6 years, 73.7% male) underwent the complete screening protocol. Liver fibrosis on biopsy was present in all patients, and classified as severe (Stages 3-4) in 68%. Median CPA was 22.5% (16.9-29.5) and correlated with individual fibrosis scores. ELF® and liver stiffness were elevated, but MELD-XI scores were low in all patients. Fibrosis severity neither correlated to ELF® and liver stiffness, nor to (semi-) quantitative fibrosis parameters on MRI/CT. Varices were present in 50% and hyperenhancing nodules in 25% of patients, both independent of fibrosis stage, but varices were associated with higher CPA values. The FALD spectrum includes both hepatic congestion and severe fibrosis, with signs of portal hypertension and hyperenhancing nodules as significant manifestations. Routine imaging, transient elastography, and serum biomarkers are unable to accurately assess severity of liver fibrosis in this cohort. Future research should focus on validating new diagnostic tools with biopsy as the reference standard.

Identifiants

pubmed: 30346512
pii: 5128919
doi: 10.1093/eurheartj/ehy620
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1057-1068

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.

Auteurs

Isabelle D Munsterman (ID)

Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Postbus 9101, Geert Grooteplein Zuid 10, HB Nijmegen, the Netherlands.

Anthonie L Duijnhouwer (AL)

Department of Cardiology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, HB Nijmegen, the Netherlands.

Timothy J Kendall (TJ)

Department of Pathology, Division of Pathology, University of Edinburgh, Douth Bridge, Edinburgh, UK.

Carolien M Bronkhorst (CM)

Department of Pathology, Jeroen Bosch Hospital, Henri Dunantstraat 15223 GZ 's-Hertogenbosch, the Netherlands.

Maxime Ronot (M)

Department of Radiology, University Hospitals Paris Nord Val de Seine, Beaujon, 100 Boulevard du Général Leclerc, Clichy, France.

Morgane van Wettere (M)

Department of Radiology, University Hospitals Paris Nord Val de Seine, Beaujon, 100 Boulevard du Général Leclerc, Clichy, France.

Arie P J van Dijk (APJ)

Department of Cardiology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, HB Nijmegen, the Netherlands.

Joost P H Drenth (JPH)

Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Postbus 9101, Geert Grooteplein Zuid 10, HB Nijmegen, the Netherlands.

Eric T T L Tjwa (ETTL)

Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Postbus 9101, Geert Grooteplein Zuid 10, HB Nijmegen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH